In the first three quarters, JXR made significant progress in the number of egg retrieval cycles in vitro fertilization (IVF)
In the nine months ending September 30, 2025, JXR significantly increased the number of IVF egg retrieval cycles, with the overall decline narrowing from -8.3% to -5.2%. The decline at the Chengdu hospital decreased from -6.1% to -1.9%, while the Shenzhen hospital's improvement was slow due to relocation plans. The decline in the number of IVF cycles in the U.S. market was in line with expectations due to the postponement of legislation. The company remains confident in the industry's prospects and future growth, benefiting from industry fundamentals, policy support, and continuous efforts
According to the Zhitong Finance APP, JXR (01951) announced that as of September 30, 2025, the company has made significant progress in the number of in vitro fertilization (IVF) egg retrieval cycles over a nine-month period. The company maintains a high level of confidence in the long-term development prospects of the industry and the future growth of the group. This confidence stems from the group's solid industry foundation, the continuous favorable policy support from the country for the industry, and the group's ongoing efforts to improve clinical outcomes, optimize patient care, and enrich service offerings.
In the third quarter of 2025, driven by a series of management and operational improvement measures, along with the positive trends observed during this period, the overall decline in the group's IVF egg retrieval cycles has slowed, narrowing from -8.3% from the first half of 2024 to the first half of 2025 to -5.2% from the first three quarters of 2024 to the first three quarters of 2025. Specifically, the IVF egg retrieval cycles at the group's flagship hospital in Chengdu have narrowed from a decline of -6.1% in the first half of 2025 to -1.9% for the nine months ending September 30, 2025. In contrast, the improvement in the IVF egg retrieval cycles at the group's Shenzhen hospital has been slower than that of the Chengdu hospital, due to the Shenzhen hospital preparing for its relocation plan at the end of 2025. In the U.S. market, the postponement of California Senate Bill SB729 (which requires commercial insurance to cover assisted reproduction) has led to delays in IVF egg retrieval cycles, and thus the decline in the group's IVF egg retrieval cycles in the U.S. business is in line with expectations
